Loading organizations...

§ Private Profile · 2477 55th St Ste 120 Boulder, CO 80301 United States
Bioprocessing, precision fermentation technology for biobased specialty chemicals, replacing traditional chemical production.
DMC Biotechnologies, Inc. has raised $46.0M across 3 funding rounds.
Key people at DMC Biotechnologies, Inc..
DMC Biotechnologies, Inc. has raised $46.0M in total across 3 funding rounds.
Founded in 2014 by Matthew Lipscomb and Michael Lynch, DMC Biotechnologies is a Boulder, Colorado company developing precision fermentation technology to produce sustainable, biobased specialty chemicals from sugars using engineered microbes. The enterprise utilizes dynamic metabolic control to make the bioprocessing of traditional chemical alternatives more predictable and efficient for B2B applications across industrial sectors. Operating with a team of over 40 employees and an additional laboratory in Research Triangle Park, North Carolina, the organization has raised more than $50 million in venture capital. This funding supports the strategic transition from third party toll manufacturing to higher margin internal production facilities to ensure better supply chain control and premium quality products. The firm is currently led by Chief Executive Officer Jim Flatt, who succeeded the founders after they were recognized as EY Entrepreneur of the Year finalists.
Key people at DMC Biotechnologies, Inc..
DMC Biotechnologies, Inc. has raised $46.0M across 3 funding rounds. Most recently, it raised $34.0M DMC Biotechnologies - Series B in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 3, 2021 | $34M Series B | — | Boulder Ventures, Breakthrough Energy Ventures, Capricorn Venture Partners, Cibus Capital, Michelin, SCG, Sofinnova Partners, Solvay Ventures | Announced |
| Jul 9, 2019 | $10.3M Series A | Joško Bobanović | Breakthrough Energy Ventures, Capricorn Venture Partners | Announced |
| Jan 9, 2018 | $1.8M Venture Round | ROB VAN DER Meij | — | Announced |
DMC Biotechnologies, Inc. has raised $46.0M in total across 3 funding rounds.
DMC Biotechnologies, Inc.'s investors include Boulder Ventures, Breakthrough Energy Ventures, Capricorn Venture Partners, Cibus Capital, Michelin, SCG, Sofinnova Partners, Solvay Ventures, Joško Bobanović, Rob van der Meij.
DMC Biotechnologies is a synthetic biology company that builds metabolic-control platforms to make microbial fermentation faster, more predictable, and more scalable for producing specialty and commodity bio-based chemicals and ingredients for food, animal feed, flavors/fragrances, and materials applications[1][2]. DMC operates R&D and commercial teams from Boulder, Colorado (and has links to a Durham, North Carolina presence), and has raised multiple financing rounds to scale its fermentation technology and applications[3][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick factual notes: DMC’s corporate profile lists founding in 2015 and locations in Boulder (with activity tied to Durham), and public materials highlight its metabolic valve/ dynamic metabolic control technology and multiple funding rounds supporting scale‑up[3][2][1].